https://www.selleckchem.com/products/akba.html
Histology demonstrated a lymphohistiocytic palisading granuloma with central necrobiotic collagen and mucin, consistent with GA. Physicians should be aware of the possibility of GA developing in patients receiving secukinumab, especially in those with predisposing factors for GA. A better understanding of secukinumab-associated GA may lead to discoveries in GA pathogenesis and reveal broader immunomodulatory effects of secukinumab.We present a rare case of dermatomyositis associated with nivolumab therapy for melanoma. Nivolumab is an immu
Like
Comment
Share
